A PALB2 mutation (509_510delGA) was present in four (0.3%) of 1413 cases with bladder cancer and in seven (0.15%) of 4702 controls (OR = 1.9; 95% CI 0.55–6.51; p = 0.5). Here, PALB2 is linked to urinary bladder cancer.